Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
37.93 USD +2.51% Intraday chart for Spyre Therapeutics, Inc. -4.84% +76.25%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Stifel Adjusts Spyre Therapeutics' Price Target to $54 From $36, Maintains Buy Rating MT
Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding CI
North American Morning Briefing : Powell Still in -2- DJ
North American Morning Briefing : Stock Futures -2- DJ
Wells Fargo Upgrades Spyre Therapeutics to Overweight From Equalweight, Raises Price Target to $35 From $12 MT
Spyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Spyre Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Spyre Therapeutics, Inc. Announces Board Changes CI
Spyre Therapeutics, Inc. announced that it has received $180 million in funding from a group of investors CI
BTIG Initiates Spyre Therapeutics With Buy Rating, Price Target is $32 MT
Stifel Adjusts Price Target on Spyre Therapeutics to $27 From $23, Keeps Buy Rating MT
Jefferies Initiates Spyre Therapeutics at Buy Rating With $31 Price Target MT
Spyre Therapeutics Agrees to Sell Shares in Private Placement for Expected Gross Proceeds of About $180 Million MT
Spyre Therapeutics, Inc. announced that it expects to receive $180 million in funding from a group of investors CI
Spyre Therapeutics, Inc.(NasdaqCM:SYRE) added to NASDAQ Composite Index CI
Aeglea BioTherapeutics, Inc. will Change its Ticker to SYRE from AGLE CI
Aeglea BioTherapeutics, Inc. will Change its Name to Spyre Therapeutics, Inc CI
Aeglea BioTherapeutics Changes Name to Spyre Therapeutics; CEO Appointed MT
Aeglea BioTherapeutics, Inc. Appoints Cameron Turtle as Chief Executive Officer CI
Aeglea BioTherapeutics, Inc. Announces Executive Changes CI
Spyre Therapeutics, Inc.(NasdaqCM:SYRE) dropped from NASDAQ Composite Index CI
North American Morning Briefing : Stock Futures Hold Near Two-Month Highs DJ
Aeglea BioTherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
North American Morning Briefing : Traders Await -2- DJ
Aeglea BioTherapeutics, Inc. Announces Appointment of Cameron Turtle as Principal Executive Officer CI
Chart Spyre Therapeutics, Inc.
More charts
Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
37 USD
Average target price
40 USD
Spread / Average Target
+8.11%
Consensus
  1. Stock
  2. Equities
  3. Stock Spyre Therapeutics, Inc. - Nasdaq
  4. News Spyre Therapeutics, Inc.
  5. Sector Update: Health Care Carried Higher by Surging Biotechs